Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rachel Laskey

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
The American Journal of Medicine|November 12, 2013
Prevalence, predictors, and outcomes in treatment-resistant hypertension in patients with coronary diseaseSripal Bangalore, Rana Fayyad, Rachel Laskey, et al.
The American Journal of Cardiology|May 6, 2014
Statin and the risk of renal-related serious adverse events: Analysis from the IDEAL, TNT, CARDS, ASPEN, SPARCL, and other placebo-controlled trialsSripal Bangalore, Rana Fayyad, G Kees Hovingh, et al.
The American Journal of Cardiology|February 1, 2015
Impact of female sex on lipid lowering, clinical outcomes, and adverse effects in atorvastatin trialsPriscilla Y Hsue, Vera A Bittner, John Betteridge, et al.
Heart (British Cardiac Society)|January 18, 2015
High-dose atorvastatin is superior to moderate-dose simvastatin in preventing peripheral arterial diseaseRobert M Stoekenbroek, S Matthijs Boekholdt, Rana Fayyad, et al.
The American Journal of Cardiology|December 13, 2016
Relation of Variability of Low-Density Lipoprotein Cholesterol and Blood Pressure to Events in Patients With Previous Myocardial Infarction from the IDEAL TrialSripal Bangalore, Rana Fayyad, Franz H Messerli, et al.
Journal of the American College of Cardiology|March 21, 2020
Atorvastatin Reduces First and Subsequent Vascular Events Across Vascular Territories: The SPARCL TrialMichael Szarek, Pierre Amarenco, Alfred Callahan, et al.
The American Journal of Cardiology|June 23, 2016
Emerging Cardiovascular Disease Biomarkers and Incident Diabetes Mellitus Risk in Statin-Treated Patients With Coronary Artery Disease (from the Treating to New Targets [TNT] Study)Benoit J Arsenault, Payal Kohli, Gilles Lambert, et al.
Journal of the American College of Cardiology|April 4, 2015
Relationship of oxidized phospholipids on apolipoprotein B-100 to cardiovascular outcomes in patients treated with intensive versus moderate atorvastatin therapy: the TNT trialYoung Sup Byun, Jun-Hee Lee, Benoit J Arsenault, et al.
International Journal of Cardiology|September 5, 2013
Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levelsMatti J Tikkanen, Rana Fayyad, Ole Faergeman, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
The American Journal of Medicine|November 12, 2013
Prevalence, predictors, and outcomes in treatment-resistant hypertension in patients with coronary diseaseSripal Bangalore, Rana Fayyad, Rachel Laskey, et al.
The American Journal of Cardiology|May 6, 2014
Statin and the risk of renal-related serious adverse events: Analysis from the IDEAL, TNT, CARDS, ASPEN, SPARCL, and other placebo-controlled trialsSripal Bangalore, Rana Fayyad, G Kees Hovingh, et al.
The American Journal of Cardiology|February 1, 2015
Impact of female sex on lipid lowering, clinical outcomes, and adverse effects in atorvastatin trialsPriscilla Y Hsue, Vera A Bittner, John Betteridge, et al.
Heart (British Cardiac Society)|January 18, 2015
High-dose atorvastatin is superior to moderate-dose simvastatin in preventing peripheral arterial diseaseRobert M Stoekenbroek, S Matthijs Boekholdt, Rana Fayyad, et al.
The American Journal of Cardiology|December 13, 2016
Relation of Variability of Low-Density Lipoprotein Cholesterol and Blood Pressure to Events in Patients With Previous Myocardial Infarction from the IDEAL TrialSripal Bangalore, Rana Fayyad, Franz H Messerli, et al.
Journal of the American College of Cardiology|March 21, 2020
Atorvastatin Reduces First and Subsequent Vascular Events Across Vascular Territories: The SPARCL TrialMichael Szarek, Pierre Amarenco, Alfred Callahan, et al.
The American Journal of Cardiology|June 23, 2016
Emerging Cardiovascular Disease Biomarkers and Incident Diabetes Mellitus Risk in Statin-Treated Patients With Coronary Artery Disease (from the Treating to New Targets [TNT] Study)Benoit J Arsenault, Payal Kohli, Gilles Lambert, et al.
Journal of the American College of Cardiology|April 4, 2015
Relationship of oxidized phospholipids on apolipoprotein B-100 to cardiovascular outcomes in patients treated with intensive versus moderate atorvastatin therapy: the TNT trialYoung Sup Byun, Jun-Hee Lee, Benoit J Arsenault, et al.
International Journal of Cardiology|September 5, 2013
Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levelsMatti J Tikkanen, Rana Fayyad, Ole Faergeman, et al.
Pageof 2